216 related articles for article (PubMed ID: 21557634)
41. Understanding dendritic cell immunotherapy in ovarian cancer.
Drakes ML; Stiff PJ
Expert Rev Anticancer Ther; 2016 Jun; 16(6):643-52. PubMed ID: 27078511
[TBL] [Abstract][Full Text] [Related]
42. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer.
Garg M; Chaurasiya D; Rana R; Jagadish N; Kanojia D; Dudha N; Kamran N; Salhan S; Bhatnagar A; Suri S; Gupta A; Suri A
Clin Cancer Res; 2007 Mar; 13(5):1421-8. PubMed ID: 17332284
[TBL] [Abstract][Full Text] [Related]
43. Cancer vaccines: a promising cancer therapy against all odds.
Silk AW; Finn OJ
Future Oncol; 2007 Jun; 3(3):299-306. PubMed ID: 17547525
[TBL] [Abstract][Full Text] [Related]
44. Antigen-presenting cell (APC) subsets in ovarian cancer.
Wilke CM; Kryczek I; Zou W
Int Rev Immunol; 2011; 30(2-3):120-6. PubMed ID: 21557638
[TBL] [Abstract][Full Text] [Related]
45. Immunity and immune suppression in human ovarian cancer.
Preston CC; Goode EL; Hartmann LC; Kalli KR; Knutson KL
Immunotherapy; 2011 Apr; 3(4):539-56. PubMed ID: 21463194
[TBL] [Abstract][Full Text] [Related]
46. Preface.
Tainsky MA; Morris RT
Cancer Metastasis Rev; 2015 Mar; 34(1):3. PubMed ID: 25648358
[No Abstract] [Full Text] [Related]
47. Opportunities in immunotherapy of ovarian cancer.
Coukos G; Tanyi J; Kandalaft LE
Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i11-i15. PubMed ID: 27141063
[TBL] [Abstract][Full Text] [Related]
48. The immunotherapy of patients with ovarian cancer.
Hwu P; Freedman RS
J Immunother; 2002; 25(3):189-201. PubMed ID: 12000860
[TBL] [Abstract][Full Text] [Related]
49. Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?
Bronte G; Cicero G; Sortino G; Pernice G; Catarella MT; D'Alia P; Cusenza S; Lo Dico S; Bronte E; Sprini D; Midiri M; Firenze A; Fiorentino E; Bazan V; Rolfo C; Russo A
Expert Opin Biol Ther; 2014 Jan; 14(1):103-14. PubMed ID: 24313266
[TBL] [Abstract][Full Text] [Related]
50. Potential target antigens for a universal vaccine in epithelial ovarian cancer.
Vermeij R; Daemen T; de Bock GH; de Graeff P; Leffers N; Lambeck A; ten Hoor KA; Hollema H; van der Zee AG; Nijman HW
Clin Dev Immunol; 2010; 2010():. PubMed ID: 20885926
[TBL] [Abstract][Full Text] [Related]
51. Immunotherapy for ovarian cancer: what are the targets of the future?
Adams SF; Benencia F
Future Oncol; 2015; 11(9):1293-6. PubMed ID: 25952776
[No Abstract] [Full Text] [Related]
52. Personalized vaccination against ovarian cancer: what are the possibilities?
Tanyi JL; George E
Expert Rev Vaccines; 2018 Nov; 17(11):955-958. PubMed ID: 30362844
[No Abstract] [Full Text] [Related]
53. Multimodality treatment warranted for ovarian cancer: immunotherapy, a prerequisite to improve prognosis for this vicious disease.
Leffers N; Daemen T; van der Zee AG; Nijman HW
Immunotherapy; 2009 Mar; 1(2):163-5. PubMed ID: 20635935
[No Abstract] [Full Text] [Related]
54. Targeted immune therapy of ovarian cancer.
Knutson KL; Karyampudi L; Lamichhane P; Preston C
Cancer Metastasis Rev; 2015 Mar; 34(1):53-74. PubMed ID: 25544369
[TBL] [Abstract][Full Text] [Related]
55. Ovarian cancer: designing effective vaccines and specific diagnostic tools.
Spinosa JP; Kanduc D
Immunotherapy; 2014; 6(1):35-41. PubMed ID: 24341882
[TBL] [Abstract][Full Text] [Related]
56. Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors.
De Felice F; Marchetti C; Palaia I; Musio D; Muzii L; Tombolini V; Panici PB
J Immunol Res; 2015; 2015():191832. PubMed ID: 26236750
[TBL] [Abstract][Full Text] [Related]
57. Immunotherapy in Ovarian Cancer.
Wang W; Liu JR; Zou W
Surg Oncol Clin N Am; 2019 Jul; 28(3):447-464. PubMed ID: 31079799
[TBL] [Abstract][Full Text] [Related]
58. Immunological treatment of ovarian cancer.
Cannon MJ; Santin AD; O'Brien TJ
Curr Opin Obstet Gynecol; 2004 Feb; 16(1):87-92. PubMed ID: 15128013
[TBL] [Abstract][Full Text] [Related]
59. Immunotherapy for ovarian cancer: recent advances and perspectives.
Zsiros E; Tanyi J; Balint K; Kandalaft LE
Curr Opin Oncol; 2014 Sep; 26(5):492-500. PubMed ID: 25036883
[TBL] [Abstract][Full Text] [Related]
60. [Immunological aspects of ovarian cancer: Therapeutic perspectives].
Nayama M; Collinet P; Salzet M; Vinatier D
J Gynecol Obstet Biol Reprod (Paris); 2016 Nov; 45(9):1020-1036. PubMed ID: 27320132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
